Skip to main content
Premium Trial:

Request an Annual Quote

Peter Wrighton-Smith

Inviata has appointed Peter Wrighton-Smith to its board of directors. He comes to Inviata's board with strategic product development and international commercialisation experience in addition to a broad understanding of the clinical service testing market. Wrighton-Smith is the current CEO and founder of Oxford Immunotec where he has overseen the company raise five rounds of venture funding prior to an IPO on NASDAQ in 2013.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.